SCHEMBL7789817

SCHEMBL7789817

CN1C=CC=CC1c1ccccc1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 1/20 0.33
AURKA O14965 1/20 0.33
DAPK3 O43293 1/20 0.33
JAK2 O60674 1/20 0.33
PRKD3 O94806 1/20 0.33
MAP4K4 O95819 1/20 0.33
PAK4 O96013 1/20 0.33
ABL1 P00519 1/20 0.33
NTRK1 P04629 1/20 0.33
LCK P06239 1/20 0.33
FYN P06241 1/20 0.33
CSF1R P07333 1/20 0.33
RET P07949 1/20 0.33
IGF1R P08069 1/20 0.33
MET P08581 1/20 0.33
PDGFRB P09619 1/20 0.33
PIM1 P11309 1/20 0.33
FGFR1 P11362 1/20 0.33
PDGFRA P16234 1/20 0.33
PRKACA P17612 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20999744 0.82 ACHE (0.32)
SCHEMBL10521307 0.80 CYP1A2 (0.36) GAA
SCHEMBL27598312 0.77 RECQL (0.34) CHRNA7RECQL
SCHEMBL27703870 0.75 ELANE (0.32) RECQL
SCHEMBL28139788 0.75 LMNA (0.38) RECQLCARM1PRMT6KDM1ADRD2
SCHEMBL27858737 0.73 RECQL (0.32) RECQLTSHR
SCHEMBL28139808 0.73 TDP1 (0.37) CARM1PRMT6TSHRKMT2ADRD2
SCHEMBL17636534 0.72 ALDH1A1 (0.33)
SCHEMBL23053142 0.72 ALDH1A1 (0.40) TSHRKMT2A
SCHEMBL19484813 0.71 MAOA (0.35) FLT3BRD4DRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106661735-A Palladium plating solution and palladium coating obtained using same 日本高纯度化学株式会社 2017-05-10 CN claimed
US-6232326-B1 SUFFICIENT TO REDUCE DOPAMINE LEVELS IN SUBCORTICAL AREAS OF THE BRAIN WITHOUT CAUSING SYMPTOMS OF PARKINSON'S DISEASE; PERMANENT OR LONG-TERM AMELIORATION OF SYMPTOMS ALPHA RESEARCH GROUP, LLC 2001-05-15 US claimed
CN-119930687-A Method for synthesizing phosphinopyridone by taking pyridine as raw material 四川大学 2025-05-06 CN disclosed
EP-3440155-B1 ORGANIC ELECTROLUMINESCENT COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING THE SAME ROHM & HAAS ELECT MATERIALS KOREA LTD (KR) 2021-02-24 EP disclosed
EP-3548494-A1 PHOTODYNAMIC THERAPEUTIC COMPOUNDS AND PHOTODYNAMIC METHODS OF TREATMENT Salt and Light Pharmaceuticals Pty. Ltd. (AU) 2019-10-09 EP disclosed
WO-2018102849-A1 PHOTODYNAMIC THERAPEUTIC COMPOUNDS AND PHOTODYNAMIC METHODS OF TREATMENT SALT AND LIGHT PHARMACEUTICALS PTY. LTD. (AU) 2018-06-14 WO disclosed
CN-106661735-A Palladium plating solution and palladium coating obtained using same 日本高纯度化学株式会社 2017-05-10 CN disclosed
CN-1249095-C Catalyst for vinyl compound polymerization and process for producing vinyl polymer IDEMITSU PETROCHEMICAL CO (JP) 2006-04-05 CN disclosed
CN-1416435-A Catalyst for vinyl compound polymerization and process for producing vinyl polymer IDEMITSU PETROCHEMICAL CO (JP) 2003-05-07 CN disclosed
CN-1321111-A Transition metal catalyst and preparation of polymer of alpha-olefin and vinyl compound IDEMITSU PETROCHEMICAL CO (JP) 2001-11-07 CN disclosed
US-20010020013-A1 Ortho-diphenol compounds, methods and pharmaceutical compositions for inhibiting parp GUILFORD PHARMACEUTICALS, INC. 2001-09-06 US disclosed
US-6232326-B1 SUFFICIENT TO REDUCE DOPAMINE LEVELS IN SUBCORTICAL AREAS OF THE BRAIN WITHOUT CAUSING SYMPTOMS OF PARKINSON'S DISEASE; PERMANENT OR LONG-TERM AMELIORATION OF SYMPTOMS ALPHA RESEARCH GROUP, LLC 2001-05-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010020013-A1 Ortho-diphenol compounds, methods and pharmaceutical compositions for inhibiting parp PARP3, PARP1, PARP2 CHEK1 28/4885AURKA 325/4885DAPK3 1253/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.